Business Insider The Morton Grove pharmaceutical company has been looking for a new drug to replace the old one that it acquired last year.
The drug maker’s chief executive officer, Andrew Mason, said the company was looking for new drugs to replace those acquired from other pharmaceutical companies.
And that means Morton is looking at a new antibiotic.
Mason told reporters in an interview with Bloomberg Businessweek that he thinks the new drug could be the single most popular antibiotic in the world.
And he thinks it could also be the cheapest.
Morton says the drug is not only cheaper than a new one it acquired from another company, but could also provide a significant boost to its business.
Mortality is a common cause of drug-resistant infections.
The cost of a new and effective drug is one of the biggest obstacles facing hospitals and pharmaceutical companies in finding new drugs.
Morton said it is considering a few other options, including an antibiotic to help patients with heart disease, lung cancer, and a vaccine.
Mossberg Pharmaceuticals announced last week it acquired Medimmune, a company that makes the drug, and it said it will make an announcement about a new medicine within the next few weeks.
The company is also trying to develop a new pill to treat the new problem.
The company, which has already been in talks with several drugmakers, did not immediately respond to a request for comment.
Malta, ItalyIn recent years, the United States has been a leading market for pharmaceuticals from countries that have been developing novel antibiotics.
It’s also a leader in making antibiotics cheaper and more accessible to the American public.
The United States, which also makes a large amount of antibiotics, has seen a surge in the number of antibiotic-resistant bacteria that cause hospital infections, including in children and pregnant women.